SCOTTSDALE, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX Venture:IXS)(www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today issued a shareholder update on several key initiatives for the 2009 calendar year.
